Bloomberg Law
Feb. 28, 2023, 4:27 PM

FDA Seeks to Further Restrict Unlawful Importation of Xylazine

Bloomberg Law Automation
Bloomberg Law Automation

The US Food and Drug Administration has taken action to restrict the unlawful entry of xylazine-active pharmaceutical ingredients and finished dosage form drug products into the US, the agency said Tuesday.

The FDA aims to prevent the drug from entering the US market for purposes such as illicitly manufactured fentanyl but also keep it available for its legitimate uses by veterinarians, the FDA said.

The import alert allows FDA staff to detain xylazine shipments if it appears to be in violation of the law, and shipments are subject to heightened scrutiny, according to the FDA.

This story was produced by ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.